Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
作者信息
Jhaveri K L, Wang X V, Makker V, Luoh S-W, Mitchell E P, Zwiebel J A, Sharon E, Gray R J, Li S, McShane L M, Rubinstein L V, Patton D, Williams P M, Hamilton S R, Conley B A, Arteaga C L, Harris L N, O'Dwyer P J, Chen A P, Flaherty K T
机构信息
Department of Medicine, Memorial Sloan-Kettering Center, New York, USA.
Biostatistics, E-A Biostatistical Center, Boston, USA.
出版信息
Ann Oncol. 2021 Aug;32(8):1068. doi: 10.1016/j.annonc.2021.05.797. Epub 2021 Jun 5.
Abstract
摘要
相似文献
1
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Ann Oncol. 2021 Aug;32(8):1068. doi: 10.1016/j.annonc.2021.05.797. Epub 2021 Jun 5.
2
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Ann Oncol. 2019 Nov 1;30(11):1821-1830. doi: 10.1093/annonc/mdz291.
3
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.
4
Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Oncologist. 2021 Aug;26(8):635-639. doi: 10.1002/onco.13715. Epub 2021 Mar 11.
5
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31.
6
Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
J Comp Eff Res. 2021 May;10(7):595-602. doi: 10.2217/cer-2020-0201. Epub 2020 Oct 23.
7
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27.
8
The role of ado-trastuzumab emtansine in current clinical practice.
J Oncol Pharm Pract. 2021 Jan;27(1):150-155. doi: 10.1177/1078155220951862. Epub 2020 Aug 24.
9
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Cancer Chemother Pharmacol. 2017 Dec;80(6):1147-1159. doi: 10.1007/s00280-017-3443-1. Epub 2017 Oct 17.
10
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Mol Cancer Ther. 2019 Oct;18(10):1721-1730. doi: 10.1158/1535-7163.MCT-19-0207. Epub 2019 Jul 10.
引用本文的文献
1
PDLIM1 Inhibits Chemoresistance by Blocking DNA Damage Repair in Gastric Cancer.
Recent Pat Anticancer Drug Discov. 2025;20(2):260-273. doi: 10.2174/0115748928307544240502064448.
Zotero 插件